Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
37.9M
-
Shares change
-
+4.99M
-
Total reported value, excl. options
-
$1.41B
-
Value change
-
+$190M
-
Put/Call ratio
-
0.79
-
Number of buys
-
77
-
Number of sells
-
-49
-
Price
-
$37.20
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q1 2017
175 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q1 2017.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.9M shares
of 49.6M outstanding shares and own 76.32% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (5.69M shares), FMR LLC (3.54M shares), WELLINGTON MANAGEMENT GROUP LLP (2.54M shares), VANGUARD GROUP INC (2.43M shares), ORBIMED ADVISORS LLC (2.25M shares), JANUS CAPITAL MANAGEMENT LLC (2.21M shares), BlackRock Inc. (1.74M shares), Redmile Group, LLC (1.73M shares), STATE STREET CORP (1.5M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.15M shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.